PCA
BIIB icon

Providence Capital Advisors’s Biogen BIIB Stock Holding History

Providence Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4
Closed -$1K – 224
2019
Q2 		$1K Sell
4
-20
-83% -$4.62K ﹤0.01% 230
2019
Q1 		$6K Buy
24
+20
+500% +$6.3K ﹤0.01% 200
2018
Q4 		$1K Hold
4
– – ﹤0.01% 244
2018
Q3 		$1K Hold
4
– – ﹤0.01% 253
2018
Q2 		$1K Hold
4
– – ﹤0.01% 247
2018
Q1 		$1K Hold
4
– – ﹤0.01% 241
2017
Q4 		$1K Buy
+4
New +$1.28K ﹤0.01% 302

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Providence Capital Advisors's BIIB Position: Q3 2019 in Review

Providence Capital Advisors sold out of Biogen (BIIB) in Q3 2019, closing a stake of 4 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in BIIB in Q4 2017 and held it in 7 quarters. The position peaked at $6K in Q1 2019. 989 funds tracked by Wall St. Rank hold BIIB as of Q3 2019.

  • Providence Capital Advisors reported no remaining Biogen position as of Q3 2019 after selling out during the quarter.
  • Providence Capital Advisors sold 4 Biogen shares in Q3 2019, an estimated $1K.
  • Providence Capital Advisors first reported a position in Biogen in Q4 2017 and held it in 7 quarters.
  • Providence Capital Advisors's Biogen position peaked at $6K in Q1 2019.
  • 989 funds tracked by Wall St. Rank held Biogen as of Q3 2019.

Based on Providence Capital Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.